Xlife Sciences AG (CHIX:XLSZ) Debt-to-Asset : 0.11 (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Xlife Sciences AG Debt-to-Asset?

Xlife Sciences AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was CHF2.23 Mil. Xlife Sciences AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was CHF53.05 Mil. Xlife Sciences AG's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was CHF509.86 Mil. Xlife Sciences AG's debt to asset for the quarter that ended in Jun. 2024 was 0.11.

Xlife Sciences AG Debt-to-Asset Historical Data

The historical data trend for Xlife Sciences AG's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xlife Sciences AG Debt-to-Asset Chart

Xlife Sciences AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.36

0.28

0.13

0.12

0.11

Xlife Sciences AG Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Asset	Get a 7-Day Free Trial						0.13	0.12	0.12	0.11	0.11

Competitive Comparison of Xlife Sciences AG's Debt-to-Asset

For the Biotechnology subindustry, Xlife Sciences AG's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xlife Sciences AG's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Xlife Sciences AG's Debt-to-Asset falls into.

Xlife Sciences AG Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Xlife Sciences AG's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.951	+	55.573)	/	511.994
	=	0.11

Xlife Sciences AG's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.228	+	53.047)	/	509.862
	=	0.11

Xlife Sciences AG (CHIX:XLSz) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Xlife Sciences AG Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Xlife Sciences AG's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Xlife Sciences AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xlife Sciences AG (CHIX:XLSz) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

XLS:Switzerland

Address

Talacker 35, Zurich, CHE, 8001

Website

https://www.xlifesciences.ch

Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial intelligence/digital medicine.

Xlife Sciences AG Headlines

No Headlines